Drug intelligence / Profile preview

lidocaine + midazolam

Development stage: Phase 4
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Intravenous, Intranasal

Overview

Lidocaine + midazolam is a drug combination used primarily for procedural sedation and analgesia. This combination leverages midazolam's sedative, anxiolytic, and amnestic properties with lidocaine's local anesthetic effects. Midazolam is a short-acting benzodiazepine that works by slowing activity in the brain to allow relaxation and decreased consciousness. Lidocaine is an amide-type local anesthetic that blocks sodium channels in neurons, preventing the transmission of pain signals. When used together, they provide effective sedation and pain control for various medical procedures.

Other names: intranasal lidocaine and midazolam

Targets

BZD site (GABA-A receptor benzodiazepine site)SCN5A (Sodium channel protein type 5 subunit alpha)GABA-B (Gamma-aminobutyric acid receptor type B)

Beyond the preview

Go deeper on lidocaine + midazolam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lidocaine + midazolam.